List of COVID-19 vaccine authorizations

For COVID-19 vaccination policy by country, see Vaccination policy § Table.

In 2025, at least 50 COVID-19 vaccines have received authorization in one or more countries — meaning they have been approved, licensed, or granted emergency use authorization by national regulatory authorities around the world in 201 country.

Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi–GSK. Seven others are under assessment by the WHO: Sputnik V, Sinopharm WIBP, Abdala, Zifivax, Corbevax, COVIran Barekat, and SCB-2019.

Of the 50 vaccines, 16 have a full or emergency authorization in only one country, 12 in ten or fewer countries, and 12 in more than ten countries.

Note that in some countries, vaccines may be authorized solely for travel purposes. They may not be approved for the general population. For example, the CoronaVac, Covishield, BBIBP-CorV and Covaxin vaccines are not part of Australia's national vaccination program; however, they are recognized for the purpose of travel to Australia.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.